Details
| Titel in Übersetzung | Individualized medicine in selected oncological diseases |
|---|---|
| Originalsprache | Mehrere Sprachen |
| Seiten (von - bis) | 131-134 |
| Seitenumfang | 4 |
| Fachzeitschrift | Public Health Forum |
| Jahrgang | 24 |
| Ausgabenummer | 2 |
| Publikationsstatus | Veröffentlicht - 1 Juni 2016 |
Abstract
The administration of targeted therapies (TT) has improved the treatment of some oncological indications. Five substances for TT in lung cancer and 11 substances for TT in breast cancer have been approved so far. An increased survival time and better response to treatment in EGFR-positive lung cancer patients as well as an increased quality of life in breast cancer could be proven. Actually, some economic and medical challenges preclude a wider application of targeted therapies in the oncology.
Schlagwörter
- breast cancer, individualized medicine, lung cancer, oncology, personalized medicine
ASJC Scopus Sachgebiete
- Medizin (insg.)
- Öffentliche Gesundheit, Umwelt- und Arbeitsmedizin
Ziele für nachhaltige Entwicklung
Zitieren
- Standard
- Harvard
- Apa
- Vancouver
- BibTex
- RIS
in: Public Health Forum, Jahrgang 24, Nr. 2, 01.06.2016, S. 131-134.
Publikation: Beitrag in Fachzeitschrift › Artikel › Forschung › Peer-Review
}
TY - JOUR
T1 - Individualisierte Medizin bei ausgewählten Krebserkrankungen
AU - Plöthner, Marika
AU - Zeidler, Jan
AU - Graf Von Der Schulenburg, Johann Matthias
PY - 2016/6/1
Y1 - 2016/6/1
N2 - The administration of targeted therapies (TT) has improved the treatment of some oncological indications. Five substances for TT in lung cancer and 11 substances for TT in breast cancer have been approved so far. An increased survival time and better response to treatment in EGFR-positive lung cancer patients as well as an increased quality of life in breast cancer could be proven. Actually, some economic and medical challenges preclude a wider application of targeted therapies in the oncology.
AB - The administration of targeted therapies (TT) has improved the treatment of some oncological indications. Five substances for TT in lung cancer and 11 substances for TT in breast cancer have been approved so far. An increased survival time and better response to treatment in EGFR-positive lung cancer patients as well as an increased quality of life in breast cancer could be proven. Actually, some economic and medical challenges preclude a wider application of targeted therapies in the oncology.
KW - breast cancer
KW - individualized medicine
KW - lung cancer
KW - oncology
KW - personalized medicine
UR - http://www.scopus.com/inward/record.url?scp=84974668158&partnerID=8YFLogxK
U2 - 10.1515/pubhef-2016-1004
DO - 10.1515/pubhef-2016-1004
M3 - Article
AN - SCOPUS:84974668158
VL - 24
SP - 131
EP - 134
JO - Public Health Forum
JF - Public Health Forum
SN - 0944-5587
IS - 2
ER -